Drugmakers

Jim Cramer has raised concerns over the constitutionality of recent drug price controls, urging pharmaceutical companies to seek an injunction. What Happened:  CNBC’s Mad Money host, Cramer, in a post on X on Monday, argued that, unlike tariffs, drug price controls fall under the...

Shares of Johnson & Johnson (NYSE:JNJ) are flat in Monday's trading. But they continue to test support. If this support breaks, it could be bearish for the entire market. This is why we have made it our Stock of the Day. The S&P 500 Index consists of 11 sectors. At varying times, each...

With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving diagnostics. For example, Mainz Biomed (NASDAQ: MYNZ) has developled ColoAlert, an affordable test for...

Warren Buffett-led Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) sharply lowered its exposure in General Motors Co (NYSE: GM), Merck & Co Inc (NYSE: MRK), AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and added positions in Kroger Inc (NYSE: KR) and Aon Plc (NYSE: AON), in...

Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) cut its positions in Apple Inc (NASDAQ: AAPL) and piled on stocks of drug, telecom, and oil companies in the latest quarter, according to filings made with the U.S. Securities and Exchange Commission.  What Happened: The Warren Buffett-led...

Analysts at Morgan Stanley turned bullish on Pfizer Inc. (NYSE: PFE) amid multiple catalysts and accretive M&A opportunities ahead. Analyst David Risinger upgraded Pfizer's stock from Equal-weight to Overweight with a price target boosted from $35 to $39. Ibrance Pfizer's pipeline is...

Depomed Inc (NASDAQ: DEPO) and activist investor Starboard Value reached an agreement which will see the drugmaker name a new CEO and add two new members to its board. Despite the latest developments, analysts at Cantor Fitzgerald aren't ready to name the stock as a buy just yet. In a report...

Shares of Mylan NV (NASDAQ: MYL) tumbled nearly 20 percent on Thursday after the company announced a massive $7.2 billion acquisition of Meda, a Sweden-based drugmaker. The stock's plunge likely prompted Vetr top raters to upgrade Mylan's stock rating to a five star out of five-star rating. In fact...